Monitoring for Acute Myeloid Leukemia and Myelodysplastic Syndrome
(MRD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to develop new tests to evaluate treatment effectiveness for individuals with Acute Myelogenous Leukemia (AML) or High Grade Myelodysplastic Syndrome (MDS). The goal is to identify patients at risk of disease recurrence after treatment. Participants sought are those being monitored or treated for AML or MDS who have not undergone strong chemotherapy or a bone marrow transplant in the past 3 months. This trial offers an opportunity to potentially enhance future treatment options for these conditions. As a Phase 2 trial, the research focuses on assessing treatment efficacy in an initial, smaller group, allowing participants to contribute to the development of effective therapies.
Why are researchers excited about this trial?
Researchers are excited about this clinical trial because it focuses on monitoring minimal residual disease (MRD) in patients with Acute Myelogenous Leukemia (AML) and High Grade Myelodysplastic Syndrome (MDS). This trial isn't about a new drug but rather a new technique for detecting MRD. Most treatments for AML and MDS rely on chemotherapy or stem cell transplants, which can be quite intense and have significant side effects. This new approach aims to precisely track even the smallest traces of cancer cells remaining after treatment, allowing for more tailored and timely interventions. By identifying MRD with greater accuracy, doctors can better predict relapses and potentially adjust treatments sooner, improving patient outcomes.
Who Is on the Research Team?
Michael W Becker, MD
Principal Investigator
University of Rochester
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive therapy for AML or MDS, aiming to achieve remission
Monitoring
Special assays are performed to identify Minimal Residual Disease by targeting a minor population of malignant cells
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.